Current Landscape of Targeted Therapy in Hormone Receptor-Positive and HER2-Negative Breast Cancer

Discussion: Targeted treatment options for HR + BC have evolved. The future of overcoming resistance to targeted therapy, novel compounds, and predictive markers are key to improving HR + BC outcomes.PMID:34064867 | PMC:PMC8161804 | DOI:10.3390/curroncol28030168

Source: Current Oncology - June 2, 2021 Category: Cancer & Oncology Authors: Samitha Andrahennadi Amer Sami Mita Manna Mehrnoosh Pauls Shahid Ahmed Source Type: research